Hugo E. Vargas – 30 December 2003 – In many transplant centres lamivudine is an important component of prophylaxis against, and treatment of, hepatitis B virus (HBV) graft infection. Drug resistant HBV species with specific polymerase mutations may emerge during lamivudine treatment. Aims: To examine the clinical consequences of graft infection by lamivudine resistant virus. Methods: The clinical course of four liver transplant patients who developed graft infection with lamivudine resistant virus was reviewed.

George N. Tzimas, Jeffrey S.T. Barkun, Peter Metrakos, Jean I. Tchervenkov – 30 December 2003

Carlos G. Fasola, Goran B. Klintmalm – 30 December 2003

M. George DeBusk, Yoogoo Kang, Cataldo Doria, Victor J. Navarro, Ignazio R. Marino, Howard R. Doyle – 30 December 2003

Gerond Lake‐Bakaar, Simon D. W. Frost – 30 December 2003

Robert H. Costa, Vladimir V. Kalinichenko, Ai‐Xuan L. Holterman, Xinhe Wang – 30 December 2003

Alan S. Perelson, Ruy M. Ribeiro, Jennifer E. Layden‐Almer, Thomas J. Layden – 30 December 2003

Kiran Bambha, W. Ray Kim – 30 December 2003

Lisa Forman, Steven Kawut, Ilene Rosen, Grace Pien, Hillary Bogner – 30 December 2003

Gundumi Aravinda Upadhya, Steven M. Strasberg – 30 December 2003 – UW solution and HTK solution are both used for cold preservation of liver allografts. Although they are about equally effective, their compositions are very different, and they were formulated using different rationales. The authors recently showed an important role for MMPs in liver preservation injury and consequently postulated that these preservation solutions contain cryptic inhibitors of MMP activity. To determine this possibility, the ability of these solutions to inhibit MMP activity was studied.